Altasciences Completes Acquisition of Preclinical Testing Business and Hires Key Staff
LAVAL, QC, Canada (October 1, 2018) — Altasciences today announced the completion of the acquisition of a preclinical testing business in Everett, Washington. This transaction will support Altasciences’ goal of being a mid-sized CRO that will provide talent and scale to support the preclinical and clinical markets while creating a new outsourcing paradigm for its clients.
"Our vision is to become the first CRO to build a service offering allowing for multiple points of entry that flows seamlessly from lead candidate selection to proof of concept. We now have more than 1,300 staff members in two countries working together to bring our customers the best possible services," said Steve Mason, Executive Vice President, Site Operations, at Altasciences.
Altasciences also confirmed today three key additions to the Seattle team who already boast significant expertise in preclinical testing. Michael Broadhurst has joined Altasciences as General Manager, Preclinical Safety Testing Operations; Francis Douville has joined as Vice President, Operations; and Julie Forget has joined as Director, Toxicology, and will oversee the Study Director group.
“We specifically hand-picked experienced individuals with whom we worked alongside for many years, back when Charles River in Montreal was known as CTBR. It was essential that we hire people that share our culture and values, and particularly our focus on delivering expert guidance with exceptional customer service. In addition, all three hires understand the importance of integrating our services to provide a coordinated outsourcing experience,” explained Chris Perkin, CEO at Altasciences.
These individuals bring many decades of relevant experience and have been specifically selected to add to Altasciences’ toxicology expertise as well as facilitate integration into the Altasciences vision of a full service early drug development CRO. Both the new hires and existing management will play an integral role as Altasciences prepares to further build and integrate large and small molecule safety testing services.
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
For more information
Our deep expertise and capabilities in a broad range of therapeutic areas encompasses preclinical and early clinical studies for both small molecules and biologics. We can manage your entire program, as well as provide comprehensive support research services and bioanalytical expertise.
Please see Therapeutic Areas for a fuller discussion of our capabilities and expertise.